title: Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers.
abstract: We have assessed the propensity of beta-adrenoceptor blockers to cause muscle cramps and to raise the serum creatine phosphokinase (CPK) level in 78 patients with essential hypertension. After a control period, a beta-adrenoceptor blocker without intrinsic sympathomimetic activity (ISA; propranolol, metoprolol or arotinolol) was administered for three months. Thereafter, the patients were randomised to receive a beta-adrenoceptor blocker with ISA (pindolol or carteolol) for three months or a beta-adrenoceptor blocker without ISA for a further three months. This pattern was continued until all beta-adrenoceptor blockers had been given. At the end of each period, CPK and CPK-MB levels were measured. Of the 78 subjects, muscle cramps occurred in 27 during treatment with pindolol and 32 during treatment with carteolol. No complaints were made by subjects treated with propranolol and arotinolol, but muscle cramps were reported in 2 treated with metoprolol. While muscle cramps were caused both by pindolol and carteolol in 16 subjects, they were caused by either of these drugs in the remainder of the subjects. Muscle cramp occurred mainly in the calves when the patients were in bed at night. Serum CPK and CPK-MB levels increased significantly during treatment with pindolol (control period vs pindolol, CPK = 96 vs 133 IU.ml-1, CPK-MB = 14 vs 18 IU.ml-1) or carteolol (CPK = 117 IU.ml-1, CPK-MB = 18 IU.ml-1) while the levels during treatment with propranolol, arotinolol and metoprolol did not change from those in the control period.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Second Department of Medicine, Tohoku University School of Medicine, Sendai, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Imai
authors.forename: N
authors.initials: N
authors.lastname: Watanabe
authors.forename: J
authors.initials: J
authors.lastname: Hashimoto
authors.forename: A
authors.initials: A
authors.lastname: Nishiyama
authors.forename: H
authors.initials: H
authors.lastname: Sakuma
authors.forename: H
authors.initials: H
authors.lastname: Sekino
authors.forename: K
authors.initials: K
authors.lastname: Omata
authors.forename: K
authors.initials: K
authors.lastname: Abe
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009120:Muscle Cramp / Q000139:chemically induced*; D009132:Muscles / Q000201:enzymology; D011788:Quality of Life
chemical_list: D000319:Adrenergic beta-Antagonists; D003402:Creatine Kinase